Selectively Bred Rats Provide a Unique Model of Vulnerability to PTSD-Like Behavior and Respond Differentially to FGF2 Augmentation Early in Life

Neuropsychopharmacology

Volumn 42, Issue 8, 2017, Pages 1706-1714

  Prater, Katherine E ^a,b   Aurbach, Elyse L ^a,b   Larcinese, Hanna K ^a   Smith, Taylor N ^a   Turner, Cortney A ^a   Blandino, Peter ^a   Watson, Stanley J ^a   Maren, Stephen ^c   Akil, Huda ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTERONE; FIBROBLAST GROWTH FACTOR 2;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DEFENSIVE BEHAVIOR; EARLY LIFE STRESS; EXPERIMENTAL TEST; FEAR CONDITIONING TEST; FREEZING; LEARNING; LOCOMOTION; MALE; NONHUMAN; OUTBRED RAT STRAIN; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; RAT STRAIN; REINFORCEMENT; SELECTIVELY BRED RAT; SPRAGUE DAWLEY RAT; VULNERABILITY; AGING; ANIMAL; CONDITIONING; DISEASE PREDISPOSITION; DRUG EFFECTS; ENVIRONMENT; FEAR; INBRED RAT STRAIN; INDIVIDUALITY; MOTOR ACTIVITY; PSYCHOLOGY;

AGING; ANIMALS; BEHAVIOR, ANIMAL; CONDITIONING (PSYCHOLOGY); DISEASE SUSCEPTIBILITY; ENVIRONMENT; EXTINCTION, PSYCHOLOGICAL; FEAR; FIBROBLAST GROWTH FACTOR 2; INDIVIDUALITY; MALE; MOTOR ACTIVITY; RATS; RATS, INBRED STRAINS; STRESS DISORDERS, POST-TRAUMATIC;

EID: 85016443648     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2017.37     Document Type: Article

References (32)

1. Aurbach EL, Inui EG, Turner CA, Hagenauer MH, Prater KE, Li JZ et al (2015). Fibroblast growth factor 9 is a novel modulator of negative affect. Proc Natl Acad Sci USA 112: 11953-11958.
2. Blanchard DC, Hynd AL, Minke KA, Minemoto T, Blanchard RJ (2001). Human defensive behaviors to threat scenarios show parallels to fear- and anxiety-related defense patterns of nonhuman mammals. Neurosci Biobehav Rev 25: 761-770.
3. Blechert J, Michael T, Vriends N, Margraf J, Wilhelm FH (2007). Fear conditioning in posttraumatic stress disorder: evidence for delayed extinction of autonomic, experiential, and behavioural responses. Behav Res Ther 45: 2019-2033.
4. Bomyea J, Risbrough V, Lang AJ (2012). A consideration of select pre-trauma factors as key vulnerabilities in PTSD. Clin Psychol Rev 32: 630-641.
5. Chaudhury S, Aurbach EL, Sharma V, Blandino P Jr., Turner CA, Watson SJ et al (2014). FGF2 is a target and a trigger of epigenetic mechanisms associated with differences in emotionality: partnership with H3K9me3. Proc Natl Acad Sci USA 111: 11834-11839.
6. Contractor AA, Armour C, Shea MT, Mota N, Pietrzak RH (2015). Latent profiles of DSM-5 PTSD symptoms and the 'Big Five' personality traits. J Anxiety Disord 37: 10-20.
7. Difede J, Cukor J, Wyka K, Olden M, Hoffman H, Lee FS et al (2014). D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial. Neuropsychopharmacology 39: 1052-1058.
8. Duclot F, Perez-Taboada I, Wright KN, Kabbaj M (2016). Prediction of individual differences in fear response by novelty seeking, and disruption of contextual fear memory reconsolidation by ketamine. Neuropharmacology 109: 293-305.
9. Fitzgerald PJ, Seemann JR, Maren S (2014). Can fear extinction be enhanced? A review of pharmacological and behavioral findings. Brain Res Bull 105: 46-60.
10. Flagel SB, Waselus M, Clinton SM, Watson SJ, Akil H (2014). Antecedents and consequences of drug abuse in rats selectively bred for high and low response to novelty. Neuropharmacology 76 (Pt B): 425-436.
11. Graham BM, Richardson R (2009). Acute systemic fibroblast growth factor-2 enhances long-term extinction of fear and reduces reinstatement in rats. Neuropsychopharmacology 34: 1875-1882.
12. Graham BM, Richardson R (2010). Fibroblast growth factor-2 enhances extinction and reduces renewal of conditioned fear. Neuropsychopharmacology 35: 1348-1355.
13. Graham BM, Richardson R (2011). Memory of fearful events: the role of fibroblast growth factor-2 in fear acquisition and extinction. Neuroscience 189: 156-169.
14. Graham BM, Richardson R (2015). Fibroblast growth factor 2 as a new approach to fighting fear. JAMA Psychiatry 72: 959-960.
15. Graham BM, Richardson R (2016). Individual differences in the expression of conditioned fear are associated with endogenous fibroblast growth factor 2. Learn Mem 23: 42-45.
16. Harrison LA, Ahn C, Adolphs R (2015). Exploring the structure of human defensive responses from judgments of threat scenarios. PLoS ONE 10: e0133682.
17. Holly EN, Miczek KA (2015). Capturing individual differences: challenges in animal models of posttraumatic stress disorder and drug abuse. Biol Psychiatry 78: 816-818.
18. Jaccard J, Becker MA (2009). Statistics for the Behavioral Sciences, 5th edn. Wadsworth/Thomson Learning: Belmont, CA, USA, 736 pp.
19. Kerman IA, Clinton SM, Bedrosian TA, Abraham AD, Rosenthal DT, Akil H et al (2011). High novelty-seeking predicts aggression and gene expression differences within defined serotonergic cell groups. Brain Res 1419: 34-45.
20. Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB (1995). Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry 52: 1048-1060.
21. Khan AA, Jacobson KC, Gardner CO, Prescott CA, Kendler KS (2005). Personality and comorbidity of common psychiatric disorders. Br J Psychiatry 186: 190-196.
22. Lommen MJ, Engelhard IM, Sijbrandij M, van den Hout MA, Hermans D (2013). Pre-trauma individual differences in extinction learning predict posttraumatic stress. Behav Res Ther 51: 63-67.
23. Maren S, Phan KL, Liberzon I (2013). The contextual brain: implications for fear conditioning, extinction and psychopathology. Nat Rev Neurosci 14: 417-428.
24. Milad MR, Pitman RK, Ellis CB, Gold AL, Shin LM, Lasko NB et al (2009). Neurobiological basis of failure to recall extinction memory in posttraumatic stress disorder. Biol Psychiatry 66: 1075-1082.
25. Milad MR, Rosenbaum BL, Simon NM (2014). Neuroscience of fear extinction: implications for assessment and treatment of fearbased and anxiety related disorders. Behav Res Ther 62: 17-23.
26. Norrholm SD, Jovanovic T, Olin IW, Sands LA, Karapanou I, Bradley B et al (2011). Fear extinction in traumatized civilians with posttraumatic stress disorder: relation to symptom severity. Biol Psychiatry 69: 556-563.
27. Orr SP, Lasko NB, Macklin ML, Pineles SL, Chang Y, Pitman RK (2012). Predicting post-trauma stress symptoms from pre-trauma psychophysiologic reactivity, personality traits and measures of psychopathology. Biol Mood Anxiety Disord 2: 8.
28. Orr SP, Metzger LJ, Lasko NB, Macklin ML, Peri T, Pitman RK (2000). De novo conditioning in trauma-exposed individuals with and without posttraumatic stress disorder. J Abnorm Psychol 109: 290-298.
29. Perez JA, Clinton SM, Turner CA, Watson SJ, Akil H (2009). A new role for FGF2 as an endogenous inhibitor of anxiety. J Neurosci 29: 6379-6387.
30. Stead JD, Clinton S, Neal C, Schneider J, Jama A, Miller S et al (2006). Selective breeding for divergence in novelty-seeking traits: heritability and enrichment in spontaneous anxiety-related behaviors. Behav Genet 36: 697-712.
31. Turner CA, Clinton SM, Thompson RC, Watson SJ Jr., Akil H (2011). Fibroblast growth factor-2 (FGF2) augmentation early in life alters hippocampal development and rescues the anxiety phenotype in vulnerable animals. Proc Natl Acad Sci USA 108: 8021-8025.
32. Turner CA, Gula EL, Taylor LP, Watson SJ, Akil H (2008). Antidepressant-like effects of intracerebroventricular FGF2 in rats. Brain Res 1224: 63-68.